Literature DB >> 31172791

Complications in type III open tibial shaft fractures treated with open reduction and internal fixation.

Abhishek S Chitnis1, Mollie Vanderkarr2, Charisse Sparks3, Jonathan McGlohorn4, Chantal E Holy1.   

Abstract

Aim: To estimate rates of fracture-related infection (FRI) and nonunion and assess the healthcare burden associated with FRI among patients with open reduction and internal fixation (ORIF) for Type III open tibial shaft fractures (TSFs).
Methods: Patients with type III TSF requiring ORIF were identified using MarketScan® Database. Healthcare utilization and total costs were compared using generalized linear models.
Results: The rates of FRI and nonunion were 35.99 and 36.94%, respectively, at 365 days. Patients with FRI had a significantly higher rate of readmission, emergency room visit and total healthcare costs compared with patients without FRI.
Conclusion: Patients with an ORIF procedure for Type III TSF have a high risk of FRI and nonunion and; FRI significantly increased the healthcare burden.

Entities:  

Keywords:  Gustilo Anderson Type III open fractures; costs; fracture-related infection; healthcare utilization; nonunion; open reduction and internal fixation; tibia shaft fractures

Mesh:

Year:  2019        PMID: 31172791     DOI: 10.2217/cer-2019-0040

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  2 in total

1.  Clinical study on orthopaedic treatment of chronic osteomyelitis with soft tissue defect in adults.

Authors:  Xinling Zhang; Xin Yang; Yujie Chen; Guanhuier Wang; Pengbing Ding; Zhenmin Zhao; Hongsen Bi
Journal:  Int Wound J       Date:  2021-12-21       Impact factor: 3.099

2.  Clinical experience of biliary T tube of immobilization of peri-pin membrane in tibial Gustilo III fracture treated with vacuum sealant drainage combined with an external fixator.

Authors:  Hui Ye; Shufeng Lin; Junfeng Zhu; Lifeng Jiang
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.